Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.
Expert Opin Pharmacother
; 17(17): 2319-2330, 2016 Dec.
Article
em En
| MEDLINE
| ID: mdl-27759440
ABSTRACT
INTRODUCTION:
Advances in acute lymphocytic leukemia (ALL) therapy has led to long-term survival rates in children. However, only 30%-40% of adults achieve long-term disease-free survival. After relapse, the outcome of salvage chemotherapy is very disappointing with less than 10% of long survival. Novel agents are therefore desperately required to improve response rates and survival, but also the quality of life of patients. Areas covered The following review is a comprehensive summary of various novel options reported over the past few years in the therapeutic area of adult ALL. Expert opinion Identifying key components involved in disease pathogenesis may lead to new approaches. In a near future, the incorporation of monoclonal antibodies and T-cell directed approaches including blinatumomab and chimeric antigen receptor T cells may increase the cure rates and may reduce the need for intensive therapy.Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Nucleosídeos de Purina
/
Pirimidinonas
/
Arabinonucleosídeos
/
Nucleotídeos de Adenina
/
Terapia de Salvação
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Descoberta de Drogas
/
Antineoplásicos
Aspecto:
Patient_preference
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Expert Opin Pharmacother
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
França